Chalmers Ventures’ Post

🚀 We're super excited to share that Q Bio has closed a $27 million strategic funding round, and we are thrilled to be part of this journey. This investment is set to turbocharge their mission of making preventive healthcare accessible and affordable for everyone. Joining the amazing existing investors at a16z Bio Health, Founders Fund and Khosla Ventures we are proud to lead this round. Why We’re Backing Q Bio: 🔍 All-In-One Health Check: Q Bio combines whole-body MRI scans with urine and blood tests, biomarkers, and your genetic & medical history to create a super detailed #digitaltwin profile. This helps catch health issues early and keep you on top of your game. 🏥 Three Game-Changing Tech Pillars: - Gemini Software: Integrates with any 3rd party MRI machines to give you clear exam summaries and risk assessments. - Mark I Full Body Scanner: This scanner can do a full-body check in just 10 minutes without the usual claustrophobia or radiation worries. Significant leap from the traditional MRI tech. - Anatomical Foundation Model (AFM): Uses AI to detect any anomalies, helping radiologists focus only on what needs a closer look. Tackling the Big Challenges: 💡 Cutting Costs, Boosting Efficiency: Q Bio's tech makes preventive health scans cheaper and faster. The Mark I scanner is low maintenance and high throughput, cutting down on costs and making multiple scans feasible, reducing false positives. Looking Ahead: This funding is all about making advanced health scans more accessible. We're thrilled to partner with Q Bio and help drive better health outcomes on a large scale. Terry Doyle TELUS Global Ventures (TGV) Mike Titkov #HealthcareInnovation #PreventiveHealth #DigitalTwin #MRI #AI #SeriesAFunding #QBio #PersonalizedHealth #HealthcareRevolution Read more about this exciting development in STAT's latest article linked in the post below.

Great to see the venture build/company creation model gaining more support ( and investment). Many congratulations to General Inception. The concept makes such good business sense, especially in the current investment environment with large investments in later stage opportunities being the trend. This leaves the earlier stages of innovation, (where the future late-stage opportunities originate) needing capitally efficient and creative approaches. We at Cumulus Oncology totally embrace and embody this approach. Great to see visionary investors getting behind this too. The blend of extensive early stage opportunities in Europe coupled with capital and highly experienced mission-focussed teams with successful track records behind them is a winning strategy.

Neuspera Medical Inc. closed its Series D funding round, raising $23 million 💰. The funding was led by Vertex Ventures HC and Treo Ventures, with participation from Action Potential Venture Capital, Windham Venture Partners, Olympus Innovation Ventures, and other strategic investors. Neuspera is making an Implantable Sacral Neuromodulation (SNM) System. This discreet, ultra-miniaturized implant is designed to provide personal control and relief from urinary urge incontinence (UUI), a common symptom of overactive bladder (OAB) affecting millions of adults. OAB can significantly impact daily life, leading to issues like depression and social stigma. The Neuspera System stands out as the least invasive sacral neuromodulation device. Its innovative design includes a pulse generator and electrode array that fit snugly within the sacral foramen, eliminating the need for invasive procedures. Patients can enjoy the benefits without noticeable scars or discomfort, regaining control of their symptoms and enhancing their quality of life. This funding will support Neuspera Medical through the anticipated U.S. FDA premarket approval (PMA) of the Neuspera System. This is a step forward in providing less invasive, adaptable treatment options for chronic illnesses. CEO of Neuspera Steffen Hovard said: “We’re excited to bring new partners on board as we approach the next significant milestone of submitting the Neuspera System for regulatory approval,” “The confidence and conviction of our new and existing investors, like Olympus Innovation Ventures, demonstrates the strength and potential of our platform technology.” #neuromodulation #neurotech #funding

Congrats to Vivalyx, an innovative Organ Vitality Tech startup based in Aachen, on successfully closing an oversubscribed seed funding round, raising above EUR 5 million. Investors include leading European Life Science and Deeptech venture capital firms such as Brightlands Venture Partners, TechVision Fonds, Arve Capital, the American Deeptech VC Goose Capital, and notable private angel investors.   The funding enables Vivalyx to finance the clinical study required for regulatory approval. This crucial step paves the way for the launch of the innovative organ preservation solution, which has the potential to extend the lifespan of donor organs and enhance their vitality. Vivalyx technology aims to significantly increase the number of organs available for transplantation, thus saving and improving the lives of patients worldwide – at significantly lower costs, considerably reduced complexity, and streamlined processes.   Thumbs up also to the international Orrick team including Ilona Schütz, David Hamala, Sven Greulich, Benedikt Migdal and further colleagues.   Orrick, Herrington & Sutcliffe LLP #medtech #lifesciences #organdonation #venturecapital #founders #innovation #TeamOrrick

PhotoPharmics, an innovator in Parkinson's disease research and treatment, today announced the successful first close of a $16 million investment round. The investment round, led by Kickstart Fund, a venture capital firm based in Salt Lake City, marks a significant milestone in PhotoPharmics' mission to revolutionize Parkinson's disease treatment. The primary purpose of this investment round is to fund a pivotal clinical trial aimed at obtaining FDA market authorization for Celeste PhotoPharmics' FDA breakthrough therapeutic device for Parkinson's disease. In research to this point, the innovative therapy has shown remarkable potential in improving overall function and quality of life for people with Parkinson's disease. Kent Savage, CEO of PhotoPharmics, expressed his gratitude for the support of investors, stating, "This investment is a pivotal moment in our journey to transform the treatment landscape for Parkinson's disease. With this funding, we are positioned to advance our research and bring hope to the millions of individuals living with Parkinson's." #medicaldevices #fdabreakthrough #parkinsonsdisease

🚀 Momentum on the Rise: Cytonics Makes a Mark on StartEngine 🌟 invest.cytonics.com We're thrilled to share that Cytonics has been featured in StartEngine's "Most Momentum" category, signaling a strong surge in interest from investors who believe in our mission to revolutionize #osteoarthritis care. 🩺 With over $404K raised and 175 dedicated investors joining our cause, we're not just building momentum; we're accelerating towards a future where osteoarthritis can be effectively targeted and treated. Our groundbreaking drug, "CYT-108," has shown promising results in preclinical studies, taking aim at the very root of osteoarthritis damage. To our community of investors and supporters: Your trust fuels our journey. Together, we're not just part of a funding round; we're part of a healthcare revolution. 💡 Here's to reaching new milestones, embracing innovation, and improving lives. Thank you for being an integral part of our story. 💼Join the movement. Invest in a future free from osteoarthritis pain: invest.cytonics.com #biotechnology #investing #crowdfunding

🚀 **Exciting News from the #HPI_Entrepreneurship_Ecosystem!** 🌟 At HPI SEED, we're proud to announce the successful seed funding round of our latest spin-off, Seqstant GmbH. An impressive €1.8 million has been raised to advance the revolution in disease detection. Seqstant stands at the forefront of pathogen diagnostics. Their goal? To revolutionize medical diagnostics and improve patient care worldwide.  🧬 Founded at Hasso Plattner Institute as a spin-off and supported by HPI School of Entrepreneurship, Seqstant GmbH has developed a groundbreaking software called #LiveGene, capable of identifying pathogens with just a single click. This marks a turning point in treating severe infections by drastically reducing diagnosis times. 💡 The funding round is heavily supported by strong partners such as Brandenburg Kapital GmbH , Impact Investments, Venture League SB21 and of course, us at HPI SEED.  🏥 In a world increasingly challenged by new pathogens, acting quickly and precisely is crucial. Seqstant is a shining example of how #digital_innovation from the #HPI_Ecosystem can make a significant contribution to global health and safety. 🔍 With CE certification in sight and the continuous development of their technology, Seqstant is well on its way to transforming pathogen diagnostics and relieving the healthcare system.  🌍 We're thrilled to be part of this journey and look forward to supporting Seqstant's path to improving global healthcare. Henri Knobloch Bernhard Renard Moritz Matthey, Ph.D. Robin Alexander Staszek Dr. Jens Schmidt-Sceery Maximilian Mense Michael Mansfeld Anna Schnekker Franz Breu Annalena Lorson David Hahn Gregor von Dulong Rebecca Lepadus Clara Petter Lothar H. Wieler Hasso Plattner Foundation Leon Stebe  #HPISEED #Innovation #HealthTech #StartUp #Investment

We are thrilled for Rutgers research team Nervana Therapeutics to be part of the inaugural Venturium Virtual Showcase, where they will present the technology they developed at Rutgers to an audience of venture capital investors, venture studios, accelerators, incubators, industry partners, and entrepreneurs. Nervana Therapeutics' technology is a cellularized nerve regeneration graft (CNRG) that will speed patient recovery from peripheral nerve injury, improve recovery of sensation and motor function, reduce the need for extra surgeries, and decrease lifetime medical and socioeconomic costs of new and poorly-recovered injuries. Venturium 2024, co-sponsored by Rutgers Research, is a curated showcase highlighting spinouts and technologies from members of the Tech Transfer Venture Consortium (TTVC), including Rutgers and fellow co-sponsors Kentucky Commercialization Ventures, Innovate Carolina, Northeastern University Center for Research Innovation (CRI), and PCI Ventures. This event embodies a movement towards collaborative growth, technological advancement, and revolutionizing access to academic venture opportunities.   #RutgersInnovation #RutgersResearch #venturium24 #techtransfer #techinnovation #techventures #ventureforward #cofounderconnection #collaborativegrowth

#Dealsdone #dealmaking #vcdeals #eudeals #ukdeals #refunded #eufunding #londondeals UK-incorporated Made With Intent, a segmentation platform for e-commerce, raised £1.5m in funding. Mercuri led the round and was joined by investors including Portfolio Ventures and Haatch. Saint-Martin-d'Hères, France-based SpinEM Robotics, which is developing a tracking system for robot-guided spinal surgery, rasied €10m in Series A funding from Spineart. London-based Swap, a SaaS platform for managing supply chain logistics, raised $9m in Series A funding. QED Investors led the round and was joined by investors including Cherry Ventures, 9900 and 2100 Ventures. Cambridge, UK-based PlaqueTec, which identifies biomarkers for the prevention of coronary artery disease, raised $8m in funding from investors including Future Fund. Aachen, Germany-based Vivalyx, which develops organ preservation solutions, raised €5m in seed funding from investors including Brightlands Venture Partners, TechVision Fonds, Arve Capital, VC Goose Capital, Springboard Health Angels and Angel Invest.